To additionally validate the connection between GAPDH and the GLO system, we both knocked down as well as pharmaceutically inhibited GAPDH in two different lung cancer cell lines and found that reducing active GAPDH in all cases enhanced both the expression as well as the activity of the GLO system, validating GAPDH as a master regulator of glucose metabolism and dicarbonyl stress, and with it, a critical drug target in lung cancer. Here, GAPDH is linked to lung carcinoma.